ArticlePediatric research2026
TIMP-2 and IGFBP7 for the differentiation of functional and intrinsic pediatric acute kidney injury.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is frequent in critically ill neonates and children, increasing morbidity and mortality. Early distinction between functional and intrinsic (structural) AKI is crucial due to divergent management strategies. While urinary calprotectin shows promise in differentiating AKI, urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding-protein 7 (IGFBP7) lack data in pediatrics. This study evaluated [TIMP-2]•[IGFBP7] ability to differentiate functional from intrinsic AKI in neonates and children.
methodsA total of 179 neonates and children (0-18 years) were included: 54 with intrinsic AKI, 22 with functional AKI, 44 without AKI and 59 apparently healthy children. Urinary [TIMP-2]•[IGFBP7] was compared to urinary calprotectin, fractional excretion of sodium (FE
resultsROC analysis for AKI diagnosis yielded AUCs of 0.76 (95% CI: 0.68-0.83) for [TIMP-2]•[IGFBP7], 0.69 (0.61-0.77) for calprotectin, 0.75 (0.66-0.84) for FE
conclusionIn this study, urinary [TIMP-2]•[IGFBP7] was inferior to urinary calprotectin, FE IMPACT: Acute kidney injury (AKI) affects up to 48% of critically ill neonates and children and is independently associated with increased morbidity and mortality. Differentiating functional from intrinsic AKI is essential due to distinct treatment strategies, yet reliable laboratory biomarkers remain scarce. This study evaluated urinary TIMP-2 and IGFBP7 for diagnostic accuracy in AKI differentiation to improve patient outcome. While urinary [TIMP-2]•[IGFBP7] effectively diagnosed AKI, its differential diagnostic accuracy was moderate. Calprotectin, fractional excretion of sodium, and protein-to-creatinine ratio showed superior discriminatory ability. Our findings contribute important evidence on biomarker use and limitations in the vulnerable neonatal and pediatric population.
Identifiers
42680793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.